NT$ 18.4
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Founded in 2002 and headquartered in New Taipei, Taiwan, Lukas Biomedical Inc. primarily develops immune cell medical technologies. These innovations are utilized for regenerative medicine and as complementary treatments for cancer. The company's operations are segmented into four distinct areas: E-commerce, Medical Management Business, Cell Product, and Pharmaceutical Market. Furthermore, it diversifies its business by wholesaling and retailing cosmetics, alongside providing housing equipment rental services.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Data is available to registered users only